Learn more about what makes the Graduate School of Biomedical Sciences at the Icahn School of Medicine at Mount Sinai (ISMMS) a leader in biomedical research and health-science training.
We are part of one of the oldest and largest teaching hospitals in the U.S., The Mount Sinai Hospital which was founded in 1852. Although relatively new to Mount Sinai (we were established in 1968), we share in its mission and vision, and have earned a reputation for outstanding education:
- In 2016, we ranked in the top 18% of Best Graduate Schools of Biological Sciences (U.S. News & World Report).
- In an independent survey conducted by Academic Analytics, our PhD programs ranked 3rd among 65 U.S. peer institutions and 7th on the organization’s list of top 20 specialized research universities in biomedical health sciences.
Our Renowned Faculty
Our training and research faculty are renowned experts in their fields. Many hold leadership positions in prestigious professional and research organizations, serve on national and international grant review panels, and are published in top-tier peer-reviewed journals. They are also frequently invited to speak at national and international conferences.
Among ISMMS’s current faculty, we count:
- 18 members of the National Academy of Medicine
- 2 members of the National Academy of Sciences among the Graduate School faculty (1 with a dual membership in the National Academy of Medicine)
- 18 faculty on Clarivate Analytics's List of the World's Most Highly Cited Researchers (2016)
Our Research Funding and Facilities
ISMMS boasts more than 250 research laboratories.
We are a leader in NIH biomedical research funding:
- We ranked #1 in NIH funding per principal research investigator in 2015, and #3 in NIH program grants (based on the latest data available from The Association of American Medical Colleges, March 2016).
- Many of our Basic Science departments also rank at the top in NIH Funding (Blue Ridge Institute for Medical Research, f.y.e. 2016). We currently rank:
- #2 in Neuroscience
- #3 in Pharmacology
- #4 in Genetics
- #4 Microbiology
We are a leader in cancer research:
- Our Tisch Cancer Institute (TCI) is an NCI-designated cancer center, 1 of only 69 institutions nationwide to receive this designation, based on scientific excellence, robust clinical research, and beneficial impact.
- In 2016, TCI joined a $50 million cancer research consortium with NCI-designated cancer centers at the University of Pennsylvania, Columbia University Medical Center, and Johns Hopkins.
Additionally, we rank #19 in Public Health clinical research NIH funding.
Our Industry and Academic Research Collaborations
We have also expanded our research capacity and opportunities for students through high-impact academic research and industry collaborations, including:
- A recent collaboration with Rensselaer Polytechnic Institute (RPI) that combines our strengths in biomedical research with RPI’s excellence in engineering and computational biology
- A new affiliation with Stony Brook University for collaboration on research projects, academic programs, and clinical trials
- A program with Verily (formerly Google Life Sciences) that offers select MD/PhD students the opportunity to complete their thesis research at Google
Our Technology and Innovation Resources
We’ve invested heavily in cutting-edge, 21st-century technologies and innovation, including:
- More than 25 shared research facilities offering the latest in high-performance computing, imaging, molecular pathology, genetic and genomic, stem cell, and other technologies
- The new Institute for Genomics and Multiscale Biology, featuring “Minerva,” a 7,680-core bioinformatics server cluster
- The Big Omics Data Engine (BODE), a Cray supercomputer with 2,484 Intel Haswell cores and 5 petabytes of storage, which maximizes computational throughput of genomics data analysis for NIH-funded genomics-based projects